Molecular mechanisms of chromium in alleviating insulin resistance

Journal of Nutritional Biochemistry

Volumn 23, Issue 4, 2012, Pages 313-319

  Hua, Yinan ^a   Clark, Suzanne ^a   Ren, Jun ^a   Sreejayan, Nair ^a  

^a UNIVERSITY OF WYOMING COLLEGE OF HEALTH SCIENCES   (United States)

Author keywords

Chromium; Insulin resistance; Type 2 diabetes

Indexed keywords

CHROMIUM; CHROMIUM DERIVATIVE; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE;

ADIPOCYTE; APOPTOSIS; BLOOD GLUCOSE MONITORING; CELL MEMBRANE; COMORBIDITY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; ENZYME BINDING; ENZYME PHOSPHORYLATION; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INSULIN RESISTANCE; LIPID PEROXIDATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PREMEDICATION; PROTEIN LOCALIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION;

CHROMIUM; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; EARLY MEDICAL INTERVENTION; EXERCISE; HUMANS; INSULIN RESISTANCE; LIFE STYLE; OBESITY; PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, INSULIN;

EID: 84858161856     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2011.11.001     Document Type: Review

References (88)

1. Ogden C.L., Carroll M.D., Curtin L.R., McDowell M.A., Tabak C.J., Flegal K.M. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006, 295:1549-1555.
2. Engelgau M.M., Geiss L.S., Saaddine J.B., Boyle J.P., Benjamin S.M., Gregg E.W., et al. The evolving diabetes burden in the United States. Ann Intern Med 2004, 140:945-950.
3. Eckel R.H., Kahn R., Robertson R.M., Rizza R.A. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation 2006, 113:2943-2946.
4. Flier J.S. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004, 116:337-350.
5. Hogan P., Dall T., Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003, 26:917-932.
6. Mokdad A.H., Ford E.S., Bowman B.A., Dietz W.H., Vinicor F., Bales V.S., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289:76-79.
7. Popkin B.M. Recent dynamics suggest selected countries catching up to US obesity. Am J Clin Nutr 2010, 91:284S-288S.
8. Flegal K.M., Carroll M.D., Ogden C.L., Curtin L.R. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303:235-241.
9. Type 2 diabetes in children and adolescents. Diabetes Care 2000, 23:381-389. American Diabetes Association.
10. Koh-Banerjee P., Wang Y., Hu F.B., Spiegelman D., Willett W.C., Rimm E.B. Changes in body weight and body fat distribution as risk factors for clinical diabetes in US men. Am J Epidemiol 2004, 159:1150-1159.
11. Muoio D.M., Newgard C.B. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol 2008, 9:193-205.
12. (accessed on July 21, 2011). http://diabetes.niddk.nih.gov/dm/pubs/statistics/#Pre-diabetesY20.
13. Haffner S.M., Stern M.P., Hazuda H.P., Mitchell B.D., Patterson J.K. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?. JAMA 1990, 263:2893-2898.
14. Gillies C.L., Abrams K.R., Lambert P.C., Cooper N.J., Sutton A.J., Hsu R.T., et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007, 334:299.
15. Mertz W., Schwarz K. Relationship of glucose tolerance to impaired intravenous glucose tolerance of rats on stock diets. Am J Physiol 1959, 196:614-618.
16. Jeejeebhoy K.N., Chu R.C., Marliss E.B., Greenberg G.R., Bruce-Robertson A. Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation, in a patient receiving long-term total parenteral nutrition. Am J Clin Nutr 1977, 30:531-538.
17. Freund H., Atamian S., Fischer J.E. Chromium deficiency during total parenteral nutrition. JAMA 1979, 241:496-498.
18. Di Bona K.R., Love S., Rhodes N.R., McAdory D., Sinha S.H., Kern N., et al. Chromium is not an essential trace element for mammals: effects of a "low-chromium" diet. J Biol Inorg Chem 2011, 16:381-390.
19. Wang Z.Q., Cefalu W.T. Current concepts about chromium supplementation in type 2 diabetes and insulin resistance. Curr Diab Rep 2010, 10:145-151.
20. Hummel M., Standl E., Schnell O. Chromium in metabolic and cardiovascular disease. Horm Metab Res 2007, 39:743-751.
21. Vincent J.B. Chromium: celebrating 50 years as an essential element?. Dalton Trans 2010, 39:3787-3794.
22. Lau F.C., Bagchi M., Sen C.K., Bagchi D. Nutrigenomic basis of beneficial effects of chromium(III) on obesity and diabetes. Mol Cell Biochem 2008, 317:1-10.
23. Balk E.M., Tatsioni A., Lichtenstein A.H., Lau J., Pittas A.G. Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes Care 2007, 30:2154-2163.
24. Kleefstra N., Houweling S.T., Bilo H.J. Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes Care 2007, 30:e102. [author reply e103].
25. Kleefstra N., Houweling S.T., Jansman F.G., Groenier K.H., Gans R.O., Meyboom-de Jong B., et al. Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial. Diabetes Care 2006, 29:521-525.
26. Wang Z.Q., Qin J., Martin J., Zhang X.H., Sereda O., Anderson R.A., et al. Phenotype of subjects with type 2 diabetes mellitus may determine clinical response to chromium supplementation. Metabolism 2007, 56:1652-1655.
27. Saltiel A.R., Kahn C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001, 414:799-806.
28. Myers M.G., White M.F. The new elements of insulin signaling. Insulin receptor substrate-1 and proteins with SH2 domains. Diabetes 1993, 42:643-650.
29. Yamamoto A., Wada O., Ono T. A low-molecular-weight, chromium-binding substance in mammals. Toxicol Appl Pharmacol 1981, 59:515-523.
30. Yamamoto A., Wada O., Ono T. Isolation of a biologically active low-molecular-mass chromium compound from rabbit liver. Eur J Biochem 1987, 165:627-631.
31. Davis C.M., Vincent J.B. Chromium oligopeptide activates insulin receptor tyrosine kinase activity. Biochemistry 1997, 36:4382-4385.
32. Yamamoto A., Wada O., Manabe S. Evidence that chromium is an essential factor for biological activity of low-molecular-weight, chromium-binding substance. Biochem Biophys Res Commun 1989, 163:189-193.
33. Vincent J.B. Quest for the molecular mechanism of chromium action and its relationship to diabetes. Nutr Rev 2000, 58:67-72.
34. Vincent J.B. Recent advances in the nutritional biochemistry of trivalent chromium. Proc Nutr Soc 2004, 63:41-47.
35. Vincent J.B. The biochemistry of chromium. J Nutr 2000, 130:715-718.
36. Chen Y., Watson H.M., Gao J., Sinha S.H., Cassady C.J., Vincent J.B. Characterization of the organic component of low-molecular-weight chromium-binding substance and its binding of chromium. J Nutr 2011, 141:1225-1232.
37. Wang H., Kruszewski A., Brautigan D.L. Cellular chromium enhances activation of insulin receptor kinase. Biochemistry 2005, 44:8167-8175.
38. Mackowiak P., Krejpcio Z., Sassek M., Kaczmarek P., Hertig I., Chmielewska J., et al. Evaluation of insulin binding and signaling activity of newly synthesized chromium(III) complexes in vitro. Mol Med Report 2010, 3:347-353.
39. Yang X., Li S.Y., Dong F., Ren J., Sreejayan N. Insulin-sensitizing and cholesterol-lowering effects of chromium (d-phenylalanine)3. J Inorg Biochem 2006, 100:1187-1193.
40. Wang Z.Q., Zhang X.H., Russell J.C., Hulver M., Cefalu W.T. Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR:LA-cp rats. J Nutr 2006, 136:415-420.
41. Yang X., Palanichamy K., Ontko A.C., Rao M.N., Fang C.X., Ren J., et al. A newly synthetic chromium complex - chromium(phenylalanine)3 improves insulin responsiveness and reduces whole body glucose tolerance. FEBS Lett 2005, 579:1458-1464.
42. Sreejayan N., Dong F., Kandadi M.R., Yang X., Ren J. Chromium alleviates glucose intolerance, insulin resistance, and hepatic ER stress in obese mice. Obesity (Silver Spring) 2008, 16:1331-1337.
43. Dong F., Kandadi M.R., Ren J., Sreejayan N. Chromium (d-phenylalanine)3 supplementation alters glucose disposal, insulin signaling, and glucose transporter-4 membrane translocation in insulin-resistant mice. J Nutr 2008, 138:1846-1851.
44. Kandadi M.R., Unnikrishnan M.K., Warrier A.K., Du M., Ren J., Sreejayan N. Chromium (d-phenylalanine)3 alleviates high fat-induced insulin resistance and lipid abnormalities. J Inorg Biochem 2011, 105:58-62.
45. Cefalu W.T., Wang Z.Q., Zhang X.H., Baldor L.C., Russell J.C. Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats. J Nutr 2002, 132:1107-1114.
46. Penumathsa S.V., Thirunavukkarasu M., Samuel S.M., Zhan L., Maulik G., Bagchi M., et al. Niacin bound chromium treatment induces myocardial Glut-4 translocation and caveolar interaction via Akt, AMPK and eNOS phosphorylation in streptozotocin induced diabetic rats after ischemia-reperfusion injury. Biochim Biophys Acta 2009, 1792:39-48.
47. Jain S.K., Croad J.L., Velusamy T., Rains J.L., Bull R. Chromium dinicocysteinate supplementation can lower blood glucose, CRP, MCP-1, ICAM-1, creatinine, apparently mediated by elevated blood vitamin C and adiponectin and inhibition of NFkappaB, Akt, and Glut-2 in livers of Zucker diabetic fatty rats. Mol Nutr Food Res 2011, 54:1371-1380.
48. Tuzcu M., Sahin N., Orhan C., Agca C.A., Akdemir F., Tuzcu Z., et al. Impact of chromium histidinate on high fat diet induced obesity in rats. Nutr Metab (Lond) 2011, 8:28.
49. Chen G., Liu P., Pattar G.R., Tackett L., Bhonagiri P., Strawbridge A.B., et al. Chromium activates glucose transporter 4 trafficking and enhances insulin-stimulated glucose transport in 3T3-L1 adipocytes via a cholesterol-dependent mechanism. Mol Endocrinol 2006, 20:857-870.
50. Pattar G.R., Tackett L., Liu P., Elmendorf J.S. Chromium picolinate positively influences the glucose transporter system via affecting cholesterol homeostasis in adipocytes cultured under hyperglycemic diabetic conditions. Mutat Res 2006, 610:93-100.
51. Sealls W., Penque B.A., Elmendorf J.S. Evidence that chromium modulates cellular cholesterol homeostasis and ABCA1 functionality impaired by hyperinsulinemia - brief report. Arterioscler Thromb Vasc Biol 2011, 31:1139-1140.
52. Cefalu W.T., Rood J., Pinsonat P., Qin J., Sereda O., Levitan L., et al. Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. Metabolism 2010, 59:755-762.
53. Rhee S.G. Cell signaling. H2O2, a necessary evil for cell signaling. Science 2006, 312:1882-1883.
54. Goldstein B.J. Protein-tyrosine phosphatases: emerging targets for therapeutic intervention in type 2 diabetes and related states of insulin resistance. J Clin Endocrinol Metab 2002, 87:2474-2480.
55. Sreejayan N., Lin Y., Hassid A. NO attenuates insulin signaling and motility in aortic smooth muscle cells via protein tyrosine phosphatase 1B-mediated mechanism. Arterioscler Thromb Vasc Biol 2002, 22:1086-1092.
56. Mahadev K., Zilbering A., Zhu L., Goldstein B.J. Insulin-stimulated hydrogen peroxide reversibly inhibits protein-tyrosine phosphatase 1b in vivo and enhances the early insulin action cascade. J Biol Chem 2001, 276:21938-21942.
57. van Montfort R.L., Congreve M., Tisi D., Carr R., Jhoti H. Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B. Nature 2003, 423:773-777.
58. Barr A.J. Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development. Future Med Chem 2010, 2:1563-1576.
59. Peters K.G., Davis M.G., Howard B.W., Pokross M., Rastogi V., Diven C., et al. Mechanism of insulin sensitization by BMOV (bis maltolato oxo vanadium); unliganded vanadium (VO4) as the active component. J Inorg Biochem 2003, 96:321-330.
60. Davis C.M., Sumrall K.H., Vincent J.B. A biologically active form of chromium may activate a membrane phosphotyrosine phosphatase (PTP). Biochemistry 1996, 35:12963-12969.
61. Goldstein B.J., Zhu L., Hager R., Zilbering A., Sun Y., vincent J.B. Enhancement of post-receptor insulin signaling by trivalent chromium in hepatoma cells is associated with differential inhibition of specific protein-tyrosine phosphatases. J Trace Elem Exp Med 2001, 14:393-401.
62. Aguirre V., Uchida T., Yenush L., Davis R., White M.F. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 2000, 275:9047-9054.
63. Sykiotis G.P., Papavassiliou A.G. Serine phosphorylation of insulin receptor substrate-1: a novel target for the reversal of insulin resistance. Mol Endocrinol 2001, 15:1864-1869.
64. Rui L., Fisher T.L., Thomas J., White M.F. Regulation of insulin/insulin-like growth factor-1 signaling by proteasome-mediated degradation of insulin receptor substrate-2. J Biol Chem 2001, 276:40362-40367.
65. Solinas G., Naugler W., Galimi F., Lee M.S., Karin M. Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. Proc Natl Acad Sci U S A 2006, 103:16454-16459.
66. Chen W.Y., Chen C.J., Liu C.H., Mao F.C. Chromium supplementation enhances insulin signalling in skeletal muscle of obese KK/HlJ diabetic mice. Diabetes Obes Metab 2009, 11:293-303.
67. Wang Y.Q., Yao M.H. Effects of chromium picolinate on glucose uptake in insulin-resistant 3T3-L1 adipocytes involve activation of p38 MAPK. J Nutr Biochem 2009, 20:982-991.
68. Nakatani Y., Kaneto H., Kawamori D., Yoshiuchi K., Hatazaki M., Matsuoka T.A., et al. Involvement of endoplasmic reticulum stress in insulin resistance and diabetes. J Biol Chem 2005, 280:847-851.
69. Hotamisligil G.S. Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes 2005, 54(Suppl 2):S73-78.
70. Ozcan U., Cao Q., Yilmaz E., Lee A.H., Iwakoshi N.N., Ozdelen E., et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004, 306:457-461.
71. Ozcan U., Yilmaz E., Ozcan L., Furuhashi M., Vaillancourt E., Smith R.O., et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006, 313:1137-1140.
72. Engin F., Hotamisligil G.S. Restoring endoplasmic reticulum function by chemical chaperones: an emerging therapeutic approach for metabolic diseases. Diabetes Obes Metab 2010, 12(Suppl 2):108-115.
73. Rains J.L., Jain S.K. Oxidative stress, insulin signaling, and diabetes. Free Radic Biol Med 2011, 50:567-575.
74. Jain S.K., Kannan K. Chromium chloride inhibits oxidative stress and TNF-alpha secretion caused by exposure to high glucose in cultured U937 monocytes. Biochem Biophys Res Commun 2001, 289:687-691.
75. Jain S.K., Lim G. Chromium chloride inhibits TNFalpha and IL-6 secretion in isolated human blood mononuclear cells exposed to high glucose. Horm Metab Res 2006, 38:60-62.
76. Jain S.K., Patel P., Rogier K. Trivalent chromium inhibits protein glycosylation and lipid peroxidation in high glucose-treated erythrocytes. Antioxid Redox Signal 2006, 8:238-241.
77. Jain S.K., Rains J.L., Croad J.L. Effect of chromium niacinate and chromium picolinate supplementation on lipid peroxidation, TNF-alpha, IL-6, CRP, glycated hemoglobin, triglycerides, and cholesterol levels in blood of streptozotocin-treated diabetic rats. Free Radic Biol Med 2007, 43:1124-1131.
78. Hazane-Puch F., Benaraba R., Valenti K., Osman M., Laporte F., Favier A., et al. Chromium III histidinate exposure modulates gene expression in HaCaT human keratinocytes exposed to oxidative stress. Biol Trace Elem Res 2010, 137:23-39.
79. Dong F., Yang X., Sreejayan N., Ren J. Chromium (d-phenylalanine)3 improves obesity-induced cardiac contractile defect in ob/ob mice. Obesity (Silver Spring) 2007, 15:2699-2711.
80. Lai M.H. Antioxidant effects and insulin resistance improvement of chromium combined with vitamin C and e supplementation for type 2 diabetes mellitus. J Clin Biochem Nutr 2008, 43:191-198.
81. Cheng H.H., Lai M.H., Hou W.C., Huang C.L. Antioxidant effects of chromium supplementation with type 2 diabetes mellitus and euglycemic subjects. J Agric Food Chem 2004, 52:1385-1389.
82. Hardie D.G., Scott J.W., Pan D.A., Hudson E.R. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett 2003, 546:113-120.
83. Kemp B.E., Stapleton D., Campbell D.J., Chen Z.P., Murthy S., Walter M., et al. AMP-activated protein kinase, super metabolic regulator. Biochem Soc Trans 2003, 31:162-168.
84. Kudo N., Barr A.J., Barr R.L., Desai S., Lopaschuk G.D. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5'-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 1995, 270:17513-17520.
85. Winder W.W., Hardie D.G. Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am J Physiol 1996, 270:E299-E304.
86. Rutter G.A., Da Silva Xavier G., Leclerc I. Roles of 5'-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis. Biochem J 2003, 375:1-16.
87. Zhao P., Wang J., Ma H., Xiao Y., He L., Tong C., et al. A newly synthetic chromium complex-chromium (d-phenylalanine)3 activates AMP-activated protein kinase and stimulates glucose transport. Biochem Pharmacol 2009, 77:1002-1010.
88. Rains J.L., Jain S.K. Hyperketonemia decreases mitochondrial membrane potential and its normalization with chromium (III) supplementation in monocytes. Mol Cell Biochem 2011, 349:77-82.